`
`DEMONSTRATIVEEXHIBIT –NOT EVIDENCE
`
`Patent Owner’s Presentation
`August 11, 2021 Oral Hearing
`
`IPR2020‐01053
`
`Slayback Pharma LLC. v. Sumitomo Dainippon Pharma Co.,
`
`Ltd.
`
`1
`
`Exhibit 2143
`Slayback v. Sumitomo
`IPR2020-01053
`
`
`
`PDX-101
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`•Obviousness (Ground 3) –Claims 1‐75 are patentable over Saji, US
`
`5,532,372, a reference previously considered by the Patent Office
`
`•Because these claims are entitled to the Provisional Filing date, Grounds 1 and 2 fail as the art relied on is
`•These claims are entitled to the August 22, 2002 provisional filing date
`•These claims recite treating “manic depressive psychosis” or treating a patient with “an anti‐psychotic.”
`56‐60, 62, 64, 66, 67, 69, 71, 73, and 75.
`
`–Grounds 1 and 2 apply only to claims 8‐18, 25‐28, 30‐31, 33‐39, 40‐44, 46, 48‐55,
`
`after that date.
`
`•Priority (Grounds 1 and 2)
`
`Overview
`
`2
`
`
`
`PDX-102
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`IPR2020-01053, Ex. 1001
`
`–Without either clinically significant weight gain or weight gain
`–Administered: Once daily, oral administration of 20‐120 mg
`–To treat schizophrenia or manic depressive psychosis
`
`•Claims cover use of lurasidone as an antipsychotic
`•75 Claims (5 independent)
`
`The Patented Invention
`
`3
`
`
`
`PDX-103
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`•See IPR2020‐01053 Petition at 21.
`bipolar disorder
`person of skill to mean
`psychoses” is understood by a
`
`–“Manic depressive
`
`•Specification refers to both
`
`–See IPR2020‐01053Ex. 1001
`schizophrenia
`psychoses,” and
`“manic depressive
`
`’827 Patent col. 2, ll. 5‐10.
`
`’827 Patent Specification Discloses Both Schizophrenia and
`
`Manic Depressive Psychoses
`
`4
`
`
`
`PDX-104
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`POR at 12-13
`
`IPR2020-01053 Ex. 2022
`
`Weight Gain is a Known and Substantial Problem
`
`5
`
`
`
`PDX-105
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`POR at 6
`
`IPR2020-01053, Ex. 2027
`
`Stahl’s Essential 2013
`
`Antipsychotics are Complex
`
`6
`
`
`
`PDX-106
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Ziprasidone –POR at 11‐12
`
`Risperidone –POR at 10‐11
`
`Quetiapine –POR at 8‐9
`
`Olanzapine –POR at 7
`
`Antipsychotics are Complex
`
`POR at 6
`
`IPR2020-01053, Ex. 2027
`
`Stahl’s Essential 2013
`
`7
`
`
`
`PDX-107
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`IPR2020-01053 Ex. 2131 ¶¶ 81-89
`
`at 81; POR at 12-13
`
`Dr. Stephen Stahl
`
`Mechanisms Underlying Weight Gain are Complex and
`
`Poorly Understood
`
`8
`
`
`
`PDX-108
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`IPR2020-01053 Ex. 2028 at 5-
`
`6; POR at 13
`
`“Weight gain . . . Difficult to Predict”
`
`9
`
`
`
`PDX-109
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`IPR2020-01053 Ex. 1001, 7:49-
`
`67
`
`Inventors Surprisingly Discovered the Novel Dosing
`
`Regimen did not Cause Weight Gain
`
`10
`
`
`
`PDX-110
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`IPR2020-01053 Ex. 1001,
`
`Claim 1
`
`Inventors Surprisingly Discovered the Novel Dosing
`
`Regimen did not Cause Weight Gain
`
`11
`
`
`
`PDX-111
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Grounds 1 and 2 –Priority
`
`12
`
`
`
`PDX-112
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`–A POSA, reading the ’927 provisional application in light of what was known about
`
`understand that the inventors were in possession of the MDP claims –POR 27‐32
`the link between schizophrenia and manic depressive psychosis (“MDP”) would
`
`–Slayback’s priority argument is legally flawed and not properly before the Board –
`
`POR at 32‐33 et seq.
`
`•Slayback’s argument fails both legally and factually:
`
`•Grounds 1 and 2 (priority) apply only to claims 8‐18, 25‐28, 30‐31, 33‐39,
`
`“antipsychotic”
`–Claims recite treating “manic depressive psychosis” or treating a patient with an
`40‐44, 46, 48‐55, 56‐60, 62, 64, 66, 67, 69, 71, 73, and 75.
`
`’827 Patent Claims Entitled to Priority to Aug. 22, 2002
`
`13
`
`
`
`PDX-113
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`U.S.C. §311
`for the MDP claims and that is not an issue properly before the Board. 35
`•Thus, the question is purely whether there is written description support
`
`filing
`August 28, 2014 filing date as they were not part of the August 28, 2014
`•Therefore, the MDP claims cannot be legally considered “entitled” to the
`
`•The MDP claims were notfiled with the August 28, 2014 application, they
`
`were added later by amendment
`
`•Slayback argues that the MDP claims are entitled to a filing date no
`
`earlier than August 28, 2014.
`
`Slayback’s Priority Argument is Legally Flawed
`
`14
`
`
`
`PDX-114
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`•Ex. 1001, 5:1‐10:25; Ex. 1005, pp. 32‐41; see Ex. 2131 (Stahl), ¶¶ 98‐99. POR 28
`MDP specifically, without weight gain.
`claimed dosing regimen could treat psychoses generally, and schizophrenia and
`–Both describe the results of a Phase IIaclinical study that demonstrated that the
`
`•The specifications of the ’927 provisional application and the ’827 patent
`
`•Compare Ex. 1001, 2:7‐39 with Ex. 1005, p. 27, line 23 to p. 28, line 4.POR 28
`depressive psychoses, and nervous breakdown (U.S. 5,532,372)”
`especially as an agent for treatment of schizophrenia, senile insanity, manic
`of compounds “useful as an antipsychotic (c.f. neuroleptic agent, antianxiety, etc.),
`–Both describe the Saji ’372 patent (IPR2020‐01053 Ex. 1009) as disclosing a genus
`are identical in all relevant respects –POR 28
`
`The MDP Claims are Entitled to the ’927 Provisional Filing
`
`Date
`
`15
`
`
`
`PDX-115
`
`
`
`5:31mozm.n=>m_._.02I._._m=._Xm_m_>_._.<N_._.mZOs_m_n_
`
`
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`.fihmdmmd
`
`
`
`
`
`
`
`n—mDVgovlmfln9.5th9.8.mvmonohwnuBmmonufiuEwE.3392“:
`
`
`
`
`
`POR 28
`
`wNm0;
`
`Ex. 1005, p. 27, line 21 -26
`
`
`
`em-R23Kma.83am
`
`
`Ex. 1001,’827 Patent, 2:5-11
`
`:AN.EmhfimmwfissRm
`
`
`
`
`
`
`
`
`
`
`
`
`
`acumenon?nowuuxugpéoon”.hp@548mu?SUE?.EDPEO.“migozom05
`
`
`
`
`
`
`
`
`
`omnom.mwdokfinofizummo“CUEHMobno““commGmmmhfiwoommo.Abofiaflfiw
`
`
`
`Jcommoflaofiohdocd3aflonohwmzcd:man33m:03ha":.wuoEmSE
`
`
`
`
`
`
`
`.«00333.86Bums:05was.“950:3Goonum:U:.933.85005GO
`
`
`
`
`
`The MDP Claims are Entitled to the ’927 Provisional Filing Date
`
`
`
`389;:3:228;R99:B8:35952:20E22:
`
`.55095GO
`
`Bad:05:2:9522downmm:a.93:
`
`
`
`2E8dEuEQONEUm,3Ems—Eu:(5%Emmacmmm3E6
`
`
`
`
`2:ha953mag.52:?EEEEmEBozfl0250“0352.56
`
`
`
`
`
`.259A29(boimtam“Emma232055:“govocoaohmmtzw
`
`anma3+3:352:,mgoEmNEME8292:moEmu—5.5-8
`
`
`2.6.5msoioq«in53,33me@3332on033:«€ng
`
`
`
`Amhmdmmd.oZ.Hmm.ma5506
`
`16
`
`16
`
`
`
`
`PDX-116
`
`9:31
`
`Ex. 2131, ¶¶ 101-102
`
`Schizophrenia and MDP are not Unrelated, Distinct
`
`Diseases
`
`mmmmmmfi.
`
`NEFSNEr.~M~N.RN“28898?mo538:8amaEon
`
`
`>63835:6880:.fl:.Hufimm.mummumwcSEE—Uwas35338:8m@5386
`
`
`_..
`5:55fiBEmEDHo:Emn_Q_>_UcmmEmEQoNEum
`
`
`
`
`
`was382:3:850m@5298?5558“€qu:3mica—Emma353506352:
`BE$559333EonHmamfiwfiaE95%33:86Hm<.NS
`
`
`
`wimmuaou3:5:canNEuEQONEuwEu:9959EButwuuoauhmmtsm329me
`
`
`
`
`33meadmica—90mm95333“.0:88wasEsuflaomEum.SH
`
`
`
`mmgoauuug“Qvisage—U2:@5033\3mmmo~_o%mg
`
`17
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`
`
`
`
`mozm.n=>m_._.02I._._m=._Xm_m_>_._.<N_._.mZOs_m_n_
`
`17
`
`
`
`
`PDX-117
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`–Slayback’s Expert, Dr. Kosten, agrees . . .
`
`•Ex. 2131, ¶ 102; Ex. 2140 –Surreplyat 3
`targeting the D2receptor
`–Antipsychotics were known to treat schizophrenia and the manic phase of MPD by
`–Psychotic symptoms are the result of excess dopamine
`
`•Ex. 2131, ¶¶ 37, 102; Ex. 2140 –Surreplyat 3
`
`–Both include psychotic symptoms
`
`•Schizophrenia and MDP are not unrelatedconditions
`
`Treating Schizophrenia is Treating the Manic Phase of MDP
`
`18
`
`
`
`PDX-118
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Ex. 2134, 34:15-17
`Dr. Thomas Kosten
`
`A. That’s correct.
`
`schizophrenia and the manic phase of bipolar disorder.
`Q. So the antispsychoticcan be used to treat both
`
`Treating Schizophrenia Treats the Manic Phase of Bipolar
`
`Disorder (MDP)
`
`19
`
`
`
`PDX-119
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Ground 3 -Obviousness
`
`20
`
`
`
`PDX-120
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`–Extrapolating From Other Chemical Structures Is Improper.
`–Receptor Binding Affinity Data Are Inconsistent and Inconclusive.
`
`•The lurasidone prior art did not disclose a weight effect.
`•Weight gain is a multifactorial process.
`•Multiple receptors are involved.
`•The relationship between pharmacological profile and weight gain was not (and is not) well understood.
`
`•A Skilled Artisan Would Have No Reasonable Expectation of Success In Achieving
`
`–The Pharmacology of Antipsychotics is Complex.
`the Claimed Invention Because the Art is Unpredictable.
`
`35 U.S.C. §103: No Reasonable Expectation of Success
`
`21
`
`
`
`PDX-121
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`•“Guideline for Industry: Dose‐Response Information to Support Drug Registration” (1994) (“ICH‐4;” Ex.
`
`1030).
`
`Drug Safety (2001) (“Wetterling;” Ex. 1042);
`(“Allison;” Ex. 1041) and Wetterling, “Bodyweight Gain with Atypical Antipsychotics: A Comparative Review,”
`•Allison, “Antipsychotic‐Induced Weight Gain: A Comprehensive Research Synthesis” Am. J. Psychiatry (1999)
`
`Various Receptors in the Brain,” Jap. J. of Neuropsychopharmacology(Dec. 1999) (“Horisawa;” Ex. 1028);
`•Horisawa, “Pharmacological Characteristics of the Novel Antipsychotic SM‐13496: Evaluation of Action on
`•“ZYPREXA® (Olanzapine) tablets.” Physicians’ Desk Reference, 55thed. (2001) (“Olanzapine;” Ex. 1039);
`•“Saji amendment” (Ex. 1026) submitted during prosecution of the Saji patent;
`the following references:
`–Although not formally part of the unpatentability ground, Slayback also relies on
`over Saji, U.S. 5,532,372 –Ex. 1009.
`
`•As the Patent Office previously determined, Claims 1‐75 are patentable
`
`Claims 1‐75 are Patentable over Saji
`
`22
`
`
`
`PDX-122
`
`POR 36‐37
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`(objections from counsel
`
`removed)
`
`Ex. 2134; 88:8-24; 89:16-
`
`90:10
`
`Dr. Thomas Kosten
`
`information. So that's not irrelevant.
`with this medication.ꞏYou need to know that
`what? I mean, they're relevant to treatment of patients
`THE WITNESS:ꞏI guess I don’t ‐‐irrelevant to
`. . .
`all of those other things are irrelevant; right?
`regimen leads to weight gain –it’s your position that
`not you give it with something else, whether or not that
`use, how often you're supposed to give it, whether or
`limitations --how much of the drug you're supposed to
`QꞏꞏSo it’s your position that all of those other
`AꞏꞏOkay.
`lurasidone molecule itself; right?
`the use of lurasidone hydrochloride are due to the
`ꞏunexpected results for any secondary consideration to
`QꞏꞏYou have a blanket statement now that any
`
`Slayback’s Expert Disagrees with Slayback
`
`23
`
`
`
`PDX-123
`
`POR 36‐37
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`(objections from counsel
`
`removed)
`
`Ex. 2134; 88:8-24; 89:16-
`
`90:10
`
`Dr. Thomas Kosten
`
`objection to them having been patented for schizophrenia.
`THE WITNESS: They were patented. I don’t have any
`A They were –
`drawn, and the claims to schizophrenia are patentable?
`QꞏꞏSo you agree that it was fair for claims to be
`BY MR. SHEAR:
`
`idea.ꞏThat was fair.
`in fact, given a patent.ꞏAnd I agree.ꞏThat’s a good
`presented for use of this in schizophrenia, which was,
`THE WITNESS:ꞏThere are data that were
`. . .
`came after that is patentable?
`after that patent published, that none of the work that
`Saji patent which covers the compound of lurasidone --
`QꞏꞏSo is it your view, Dr. Kosten, that after the
`
`Slayback’s Expert Disagrees with Slayback
`
`24
`
`
`
`PDX-124
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`IPR2020-01053 Ex. 1001,
`
`Claim 1
`
`Saji ’372 Patent does not Teach the Claimed Dosing
`
`Regimen
`
`25
`
`
`
`PDX-125
`
`£331mozm_n=>m_._.02I._._m_=._xm_m_>_._.<~_._.szEm_n_
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`
`
`
`
`
`
`understood
`mechanisms of which are entirely complex and poorly
`
`
`
`
`
`9:62%EmEEScammE£>cmgammago:800.
`
`
`
`
`
`>208tammeE828chEnFEESU6mEmEmgumE
`
`•Does not teach anything about weight gain, the
`•Discloses varying dosing frequencies
`
`
`
`
`
`86528:mc_mo_omart?mmmoUmE.
`
`POR 37‐40
`Ex. 1009
`
`91mmom.
`
`%2am
`
`Saji ’372 Patent
`
`32$3m.3%
`
`26
`
`mncsoqEOU9622:58895.
`OK@613382228mm>>.
`
`3223::B_
`nooyemnc:
`
`
`
`2.5,:5:ES}.rim.»“5::a
`
`
`
`:,..
`
`ns—ligl-lllill
`
`
`
`um:8mFEESUS25:5:328320mart?mmmoUmE.7.,m
`
`•Discloses varying dose amounts, none of which are tied
`•Discloses billions of compounds
`•Was considered by the PTO
`
`to lurasidone
`
`Saji ’372 Patent
`
`238N?:8
`
`
`
`
`
`26
`
`
`
`
`
`PDX-126
`
`
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`$331mozm—n=>m_._.02I._._m=._Xm_m_>_._.<m_._.mZO_2m_n_
`
`
`
`3.8m35.92%N.63.6%axocofiadata”13:3
`
`
`
`.213wmm2:.3IIEnEI23...“.IZA1UEa.
`
`
`
`uEnnKuhnfin.“Ui.fl.D“Emmaingnu—umhfiufiip
`
`
`
`in."aat;132.5.33$9.22353EB.2“qu
`
`
`
`
`
`
`
`amcanHanoi:“Enhacxfi.832.733.533.3En
`
`
`
`45w»Euuhflnnn5anER:£935.6%Ea
`
`
`
`
`
`
`
`
`Ex. 1009 at Abstract
`
`35.33..$2am
`
`
`
`._........6._.§9-..fils_.ia25!...E.
`
`
`
`22.£1..1.
`
`
`
`i....23..
`
`
`
`3.32.E...22.523
`
`
`
`55£512.»:3......
`
`
`
`.52157a:
`
`55...;asc...
`
`27
`
`
` a:a._..a.1.1t5.6
`"Ham.“5.E.E3...—msfim3:5
`
`
`
`
`.52;-Eslifigifi
`
`E...:1it}?!E.
`
`_:_
`
`E.5:1.55..
`
`
`
`,.§.i§x.mzz§asit.a:
`
`
`
`
`
`.ami:.5...)innit;
`
`
`
`
`
`
`
`mis?»3.deanEmumifiinis.»9353..E”JRE:”NB..33BEE=1and...Bu:vana:5....13....nus—2
`
`
`
`
`
`SajiDiscloses Billions Of Compounds
`
`E.
`
`m
`
`
`
`:_XL.
`
`aghastFE
`
`”23?...“an.noc53635?:E...
`
`£3.532.:no95%mM.H
`
`Engage.
`
`
`
`m:w."E:5.EEEnasal.v.53:35.33E:533E
`
`”292:0.“”.5E:25aa.n.J3_uasBug—m
`
`IguzuTalifiul
`
`
`
`
`
`5:35...mem5...2055;?BHEE.E:w3J.EEK.E.
`
`
`
`3mm.Efi;EgonntmnEMuEdthHBBEa5......33
`
`
`
`
`
`22th5.32ESEam5.:BEHEEEumanEéa:
`
`
`
`mtcsogEouU.0mco____m_88629
`
`
`
`ucnFM!an5:332:33hfinnmfinEmumamas132m
`
`
`
`
`
`27
`
`
`
`
`
`
`
`
`PDX-127
`
`SEE
`
` mozm.n=>m_._.02I._._m=._Xm_m_>_._.<N_._.mZOs_m_n_
`.mEooofi9flSons89aLE3%baam.8:35am953mbfiuofimup35a.852:EH2588:3mequ
`82::Emmam5womanon,$83%Pamdozen?
`
`05HESomeou05.Eufimn2:moEms;Eaown.8035?
`38335hoammoE.mEon9mdEons89abfifiwo‘a
`.mE9:9adBonnSch.888mamama98:osmhfl
`
`-EEvm35mo385“ME093mBoshBob39.80qu
`on“:33339%85>:dmoEwEouowbananas—EwanE5e@5358Qua:2:weummmou0523>»E
`
`.moE:89:Eo»:EGong“.
`
`
`
`Saji Teaches Very Little About Dosing
`
`38¢58:2::>a>88mm:5mm
`
`Ex. 1009 at 12:15-24
`
`
`
`VNATNN:9as:.km
`
`
`
`
`
`,.,Ewan.5.5m.35
`
`
`
`.52
`
`28
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`
`
`
`
`28
`
`
`
`
`
`PDX-128
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Saji5,532,372
`
`SajiSilent Regarding Weight Gain
`
`29
`
`
`
`PDX-129
`
`
`
`
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`
`
`$331mozm.n=>m_._.02I._._m=._Xm_m_>_._.<N_._.mZO_>_m_n_
`
`Horisawa does not Establish that Lack of Weight Gain was
`
`
`
`mm;5.3Em_m>>U6v_um._emffizgfimmHo:82omimmtoz
`
`Expected
`
`3",,a:93.”.
`
`£3332F 85¢me
`.BofiaaEfi.32fl£0583ufimfi284m.52baa.“mi
`
`
`355::033-3%:2:Emma—5wasdatum«3.283.8330.—nhm-mEa”QE.»2555?aflab—@833
`
`
`
`
`
`38b»25:ommoiuv35:8was539?boa—5:“.m::2:
`
`
`.23m:3:83#330.8gramwamaubfi5%?3:598
`
`Saab“«63ficfifisaabfiMmficwe:2:~3me£36.”2:
`
`-9?$53»:252658.“2:.8caromE3:82—uzamw98
`
`253i$05825E555«5SB
`
`
`
`hue—3«a:29.5.?nah—oz
`
`
`
`
`
`Ex. 1028 at 3
`
`
`
`m:9mms.km
`
`7“
`
`
`’QEEEEEEhEm—fina
`
`fi
`
`30
`
`$0236>
`
`$9.83
`
`ac13.5.._.«$535.
`
`30
`
`
`
`
`
`PDX-130
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`POR at 43
`
`Ex. 2028 at pp. 5-6
`
`Receptor Binding Affinity Does Not Predict Weight Gain
`
`31
`
`
`
`PDX-131
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`POR at 43
`Ex. 2035 at 1
`
`Receptor Binding Affinity Does Not Predict Weight Gain
`
`32
`
`
`
`PDX-132
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Ziprasidone –Does Not Cause Weight Gain
`
`POR at 43
`
`IPR2020-01053, Ex. 2027
`
`Stahl’s Essential 2013
`
`Quetiapine –Causes Weight Gain
`
`Olanzapine –Causes Weight Gain
`
`Receptor Binding Affinity Does Not Predict Weight Gain
`
`33
`
`
`
`PDX-133
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Ziprasidone
`
`Lurasidone
`
`•BUT: Lurasidone Is NotStructurally Similar To Ziprasidone. Ziprasidone
`
`has an indole structure. Lurasidonedoes not.
`
`•Slayback, relying on Allison and Wetterling, argues that lack of weight
`
`lurasidone and did not cause weight gain.
`gain was expected because ziprasidone is structurally similar to
`
`35 U.S.C. §103: Unpredictability of the Claimed Invention
`
`34
`
`
`
`PDX-134
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`–Binding affinities are quite different
`
`for treating bipolar depression.
`–Lurasidoneis indicated for treating bipolar depression. Ziprasidone is not indicated
`
`–Ziprasidone causes QT prolongation, which required a black box warning on its
`
`label. Lurasidonedoes not cause QT prolongation.
`
`•Ziprasidone and lurasidonehave very different properties:
`
`35 U.S.C. §103: Unpredictability of the Claimed Invention
`
`35
`
`
`
`PDX-135
`
`POR 49
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`Ziprasidone and Lurasidone have Different Receptor
`
`Binding Profiles
`
`36
`
`
`
`PDX-136
`
`$381
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`
`
`._.02I._._m=._Xm_m_>_._.<m_._.wZOs_m_n_
`
`
`
`gozfi:_Eu=uwamacocoa“:239:.“:mwow—Eu”PE2:35.259
`
`
`
`
`
`
`
`Ex. 2131, ¶¶ 148-149
`
`37
`
`:mcmEszUS
`
`Lack of Weight Gain was not Expected Based on “Diversity
`
`
`
`
`
`35529::0vmmmmvmtmgxm“0:mm;Emu393$U6v_um._
`
`of Humans”
`
` mozm.n=>m_
`lgfluwuwcu5floaty2.5noEwan—Ea2:55¢25%»;
`
`
`
`
`.mp6a2E533ufiuuzaan.555baa:28:3256.9538you.maugaininga
`:83;<.ouumnmfi_autumnafisnnobays“.2::2:o.2%Evans—aEEnmEmmy:
`
`wasgash—Pam5ucfimbmucao.956%:3?32.5.5mocow—um<.03
`
`
`:2:5352.5.52:?b55330«5&2.a:E.3%.;:23!.5.wE
`
`
`
`
`
`
`
`o.EEEutG2.0%“...22.:352333.36.::2...uNEMSE2:95:6?@268.3
`
`5:2:95Exmbaggagesambaa45:8Bwim«we3.5%“:on.nowomanSm
`
`
`
`
`Emu—baa3.53:5Ho3%Ems»,3:38:2:955:.memime—uBEE?2:
`
`
`
`E3Eat—a12635553w.>5“>5:mEEEBEu:o@35quanE:2.5.:Mac
`
`37
`
`
`
`PDX-137
`
`E331
`
`Ex. 2134, 42:4-13
`Dr. Thomas Kosten
`
`EMmafia:«n
`
`2-meFEWgm
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`
`
`
`
`
`
`
`
`mozmosm._.02I._._m=._Xm_m_>_._.<N_._.mZO_>_m_n_rum.
`
`Lack of Weight Gain is not Inherent
`
`mH.50h«H0 E825Hocm_EmuEmfigU6v_um._
`nounommH.§ohHAI::mdosu.mGmemfi
`
`
`95mu.do>mg50%find.hHw>oomfivmUHfiMmooafiflfifimfiunfl
`
`
`wHuuMHmm.uH.mmumfiwumAna;mamafiaMfihHMMHnUfiuumm
`
`
`
`HmfiuoGMuflm.mowvdumunadouEon“unavohmouHovumn
`
`
`HahnnofiumEH0mfifiufiomummHH.=ohflflmmmfivflumHmfififim
`
`
`
`
`
`
`
`.unmfl03uvnfimmmamfifinmunohHwauonk0»mmomonu
`
`
`
`.uuhdownwmmounfiunummum
`
`38
`
`38
`
`
`
`
`PDX-138
`
`mmtxal
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`mozmQ>MHOZ.HszXmm>F<mhmZOEmo
`
`Ex. 2134, 84:24-85:3
`Dr. Thomas Kosten
`
`
`
`muwmfimuwmhwmwmRm
`
`
`
`=§me~33:3:HQ
`
`Lack of Weight Gain is not Inherent
`
`cm0 289::“0:m_EmwEm_w>>U6v_um._
`.3onxu.novHow.umnuumumwuHm>wnhummfiou03Hm
`
`
`
`
`
`hounmflwsdfimmcasesmwnumamomfimumflaafificommafixmu
`
`
`
`
`.unfiomUMMfiuwmmwanOuu-umfihH.hHHOm
`mnowEOmnonHoHanumgkmmuwhumwbmgno»on"£m50£u
`
`
`muoq
`
`39
`
`39
`
`
`
`
`PDX-139
`
`DEMONSTRATIVE EXHIBIT –NOT EVIDENCE
`
`•Slayback’s nexus argument is contrary to established law
`
`•Slayback fails to rebut Patent Owner’s objective evidence of
`
`nonobviousness
`
`Objective Indicia
`
`40
`
`